[go: up one dir, main page]

HN2008001324A - Flavivirus seudo infeccioso y usos del mismo - Google Patents

Flavivirus seudo infeccioso y usos del mismo

Info

Publication number
HN2008001324A
HN2008001324A HN2008001324A HN2008001324A HN2008001324A HN 2008001324 A HN2008001324 A HN 2008001324A HN 2008001324 A HN2008001324 A HN 2008001324A HN 2008001324 A HN2008001324 A HN 2008001324A HN 2008001324 A HN2008001324 A HN 2008001324A
Authority
HN
Honduras
Prior art keywords
seudo
flavivirus
infectious
virus
infeccious
Prior art date
Application number
HN2008001324A
Other languages
English (en)
Inventor
Frolov Ilya
Frolova Elena
c mason Peter
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of HN2008001324A publication Critical patent/HN2008001324A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION DIVULGA UN DEFICIT DE LA REPLICA DEL VIRUS SEUDO INFECCIOSO PERTENECIENTE A LA FAMILIA FLAVIVIRIDAE QUE CARECE DEL GEN CAPSIDA, DONDE LA DEFICIENCIA DE LA REPLICA DEL VIRUS SEUDO INFECCIOSO SE PROPAGA SOLO EN CELULAS QUE EXPRESAN LA CAPSIDA O CAPSIDA PRM Y ENVUELVEN LA PROTEINA DEL FLAVIVIRUS. LA PRESENTE REVELA TAMBIEN EL METODO DE PRODUCCION DE ESTE TIPO DE VIRUS A GRAN ESCALA Y EL USO DE ESTOS VIRUS SEUDO INFECCIOSO COMO VACUNAS PARA PREVENIR ENFERMEDADES CAUSADAS POR INFECCIONES DE SERES HUMANOS O ANIMALES POR LOS VIRUS QUE PERTENECEN A ESTA FAMILIA
HN2008001324A 2006-02-27 2008-08-27 Flavivirus seudo infeccioso y usos del mismo HN2008001324A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77718906P 2006-02-27 2006-02-27

Publications (1)

Publication Number Publication Date
HN2008001324A true HN2008001324A (es) 2010-10-29

Family

ID=38438014

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2008001324A HN2008001324A (es) 2006-02-27 2008-08-27 Flavivirus seudo infeccioso y usos del mismo

Country Status (20)

Country Link
US (2) US8252574B2 (es)
EP (1) EP1991709B1 (es)
JP (2) JP5538729B2 (es)
KR (1) KR101499750B1 (es)
CN (1) CN101454022B (es)
AP (1) AP2008004629A0 (es)
AU (1) AU2007217352B2 (es)
BR (1) BRPI0708332A2 (es)
CA (1) CA2643819C (es)
CO (1) CO6141481A2 (es)
CR (1) CR10323A (es)
EA (1) EA016490B1 (es)
HN (1) HN2008001324A (es)
IL (1) IL193522A (es)
MY (1) MY151062A (es)
NZ (1) NZ570881A (es)
SG (1) SG172642A1 (es)
UA (1) UA101597C2 (es)
WO (1) WO2007098267A2 (es)
ZA (1) ZA200807544B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008505656A (ja) * 2004-07-12 2008-02-28 テンジェン バイオメディカル カンパニー フラビウイルスワクチン
US8252574B2 (en) 2006-02-27 2012-08-28 The Board Of Regents Of The University Of Texas System Pseudoinfectious flavivirus and uses thereof
CA2717499A1 (en) 2008-03-14 2009-09-17 Sanofi Pasteur Biologics Co. Replication-defective flavivirus vaccines and vaccine vectors
CA2755257A1 (en) * 2009-03-16 2010-09-23 Sanofi Pasteur Biologics Co. Replication-defective flavivirus vaccine vectors against respiratory syncytial virus
US8568739B2 (en) 2009-05-28 2013-10-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antigenic chimeric tick-borne encephalitis virus/dengue virus type 4 recombinant viruses
BRPI0914507A2 (pt) * 2009-12-23 2012-04-10 Fundacao Oswaldo Cruz vacina para lentivìrus baseada em vìrus recombinante vacinal da febre amarela
WO2012027473A2 (en) * 2010-08-24 2012-03-01 The University Of North Carolina At Chapel Hill Immunogenic compositions comprising alphavirus vectored dengue virus e protein antigens
US9402890B2 (en) * 2011-02-01 2016-08-02 Uab Research Foundation Methods and compositions for pseudoinfectious alphaviruses
SG10201510800PA (en) * 2012-01-09 2016-01-28 Sanofi Pasteur Biologics Llc Purification of flaviviruses
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
US8961995B2 (en) * 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
JP6747983B2 (ja) * 2014-06-20 2020-08-26 ユニヴェルシテ デクス−マルセイユ 感染性ｒｎａウイルスを迅速に生成するための方法
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
US11149255B2 (en) * 2016-09-06 2021-10-19 Bioventures, Llc Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors
US10590171B2 (en) 2016-10-28 2020-03-17 The Board Of Regents Of The University Of Texas System Exosomes and methods of making and using the same
US11730801B2 (en) * 2017-02-14 2023-08-22 Board Of Regents, The University Of Texas System Live attenuated Zika virus with 3'UTR deletion, vaccine containing and use thereof
KR20200003390A (ko) 2017-05-08 2020-01-09 그릿스톤 온콜로지, 인코포레이티드 알파바이러스 신생항원 벡터
EP3735271A4 (en) 2018-01-04 2022-06-15 Iconic Therapeutics, Inc. ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY DRUG CONJUGATES AND RELATED METHODS
WO2020243719A1 (en) 2019-05-30 2020-12-03 Gritstone Oncology, Inc. Modified adenoviruses
IL294290A (en) 2019-12-31 2022-08-01 Elixirgen Therapeutics Inc Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
US11759515B2 (en) 2020-03-09 2023-09-19 Arcturus Therapeutics, Inc. Compositions and methods for inducing immune responses
GB2605312B (en) 2020-03-23 2024-06-26 Hdt Bio Corp Compositions and methods for delivery of RNA
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
WO2022036170A1 (en) 2020-08-14 2022-02-17 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
JPWO2022249757A1 (es) * 2021-05-27 2022-12-01
WO2023049753A2 (en) * 2021-09-22 2023-03-30 Hdt Bio Corp. Compositions and methods for enhanced antigen binding proteins
AU2022351009A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Rna vaccines against infectious diseases
WO2023049636A2 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Cancer therapy compositions and uses thereof
WO2025156270A1 (zh) * 2024-01-26 2025-07-31 洪明奇 黄病毒微型复制子、感染性颗粒、制备方法及医药组合物
WO2025264141A1 (ru) * 2024-06-18 2025-12-26 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Иммунобиологическое средство для профилактики заболеваний, вызванных вирусом клещевого энцефалита на основе мрнк
CN120818539B (zh) * 2025-09-16 2025-12-09 成都锦城学院 黄病毒的复制依赖的rna重组实验系统的建立和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2311395C (en) 1997-11-28 2006-11-28 The Crown In The Right Of The Queensland Department Of Health Flavivirus expression and delivery system
CA2341354C (en) 1998-09-02 2009-10-20 The Government Of The United States Of America Dengue viruses that are replication defective in mosquitos for use as vaccines
WO2000055378A1 (en) 1999-03-16 2000-09-21 Dana-Farber Cancer Institute, Inc. Lentiviral vector system for high quantity screening
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
WO2002072803A2 (en) 2001-03-09 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Subgenomic replicons of the flavivirus dengue
WO2003046189A1 (en) 2001-11-26 2003-06-05 The University Of Queensland Flavivirus vaccine delivery system
BR0313113A (pt) 2002-08-13 2005-06-28 Akzo Nobel Nv Replicon de um pestivìrus partìcula viral infecciosa de pestivìrus, método para a produção da mesma, e, vacina
AU2003260769A1 (en) 2002-09-03 2004-03-29 Oxford Biomedica (Uk) Limited Retroviral vector and stable packaging cell lines
CA2503303A1 (en) * 2002-11-08 2004-05-27 The Administrators Of The Tulane Educational Fund Flavivirus fusion inhibitors
WO2004055161A2 (en) 2002-12-12 2004-07-01 The Board Of Regents Of The University Of Texas System Large scale production of packaged alphavirus replicons
EP1593738A4 (en) 2003-01-30 2006-05-31 Shanghai Tengen Biomedical Co VIRUSELY PARTICULATE VACCINE WITH RECOMBINANT DENGUEVIRUS REPLICANT AS ITS SUPPORT
ES2524048T3 (es) * 2003-03-31 2014-12-03 F. Hoffmann-La Roche Ag Composiciones y métodos para la detección de ciertos flavivirus, incluidos los miembros del serogrupo del virus de la encefalitis japonesa
AU2003902842A0 (en) 2003-06-06 2003-06-26 The University Of Queensland Flavivirus replicon packaging system
JP2008505656A (ja) 2004-07-12 2008-02-28 テンジェン バイオメディカル カンパニー フラビウイルスワクチン
US8252574B2 (en) 2006-02-27 2012-08-28 The Board Of Regents Of The University Of Texas System Pseudoinfectious flavivirus and uses thereof

Also Published As

Publication number Publication date
CO6141481A2 (es) 2010-03-19
AU2007217352A1 (en) 2007-08-30
ZA200807544B (en) 2009-11-25
US20090155301A1 (en) 2009-06-18
EP1991709B1 (en) 2017-01-25
CN101454022A (zh) 2009-06-10
JP2014121324A (ja) 2014-07-03
CA2643819C (en) 2018-11-27
EP1991709A4 (en) 2009-10-21
CR10323A (es) 2009-01-29
EA016490B1 (ru) 2012-05-30
US9273288B2 (en) 2016-03-01
NZ570881A (en) 2011-09-30
KR20090008193A (ko) 2009-01-21
IL193522A (en) 2014-05-28
CA2643819A1 (en) 2007-08-30
US20130023031A1 (en) 2013-01-24
UA101597C2 (uk) 2013-04-25
IL193522A0 (en) 2009-05-04
WO2007098267A2 (en) 2007-08-30
JP2009528032A (ja) 2009-08-06
BRPI0708332A2 (pt) 2011-05-24
WO2007098267A3 (en) 2008-11-20
JP5538729B2 (ja) 2014-07-02
US8252574B2 (en) 2012-08-28
KR101499750B1 (ko) 2015-03-06
MY151062A (en) 2014-03-31
SG172642A1 (en) 2011-07-28
AP2008004629A0 (en) 2008-10-31
EA200870304A1 (ru) 2009-02-27
EP1991709A2 (en) 2008-11-19
CN101454022B (zh) 2013-09-04
AU2007217352B2 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
HN2008001324A (es) Flavivirus seudo infeccioso y usos del mismo
HN2008000087A (es) Inhibidores de la proteasa ns3 del vhc
BR112012007234A2 (pt) combinação farmacêutica compreendendo inibidor de dpp-4 e metformina, bem como seu uso e seu processo de preparação
GT200900097A (es) Inhibidores de la proteasa ns3 del hcv.
CR9678A (es) 7- aza-indazoles sustituidos , composiciones que los contienen, procedimiento de fabricacion y utilizacion
HN2005000795A (es) Pirimidinas como antagonistas del receptor de prostaglandina d2
PA8617701A1 (es) Nuevos compuestos farmaceuticos
ECSP066794A (es) Nuevos compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c
CR11221A (es) Estirpes celulares aviares inmortalizadas
ECSP11011389A (es) Compuestos orgánicos y sus usos
AR065984A1 (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. composiciones farmaceuticas.
BRPI0412902A (pt) compostos contendo imidazo substituìdo por oxima
DOP2011000366A (es) Pirazinilpirazoles
GT200600339A (es) Inhibidores macrociclicos del virus de la hepatitis c
UY32916A (es) Nuevas pirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones
NI201100172A (es) Inhibidores de la replicación del virus de la hepatitis c
CR11130A (es) Acidos benzoilamino-indan-2-carboxilicos sustituidos y compuestos relacionados
CR10900A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso los mismos
SV2011003796A (es) Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c
UY32411A (es) DERIVADOS DE 4-AMINO-7,8-DIHIDROPIRIDO [4,3-d] PIRIMIDIN-5 (6H)-ONA
AR084652A1 (es) Glicoles como agentes inactivadores de patogenos
HN2011002578A (es) Nuevos derivados de compuestos de [3,2-c]pirazol esteroidal con actividad clucocorticoide.
HN2010000330A (es) DERIVADOS DE INDOL-2-ONA DISUSTITUIDOS EN 3 y SU PREPARACION
PA8654701A1 (es) Indoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
UY33040A (es) Nuevas formas polimorfas de {4,6diamino-2-[1-(2-fluorobencil-1h-pirazol[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo